The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies and targets both the NTD and the RBD
Published in 2021 by
F. Amanat,
M. Thapa,
T. Lei,
S. M. Sayed Ahmed,
D. C. Adelsberg,
J. M. Carreno,
S. Strohmeier,
A. J. Schmitz 
,
S. Zafar,
J. Q. Zhou,
W. Rijnink,
H. Alshammary,
N. Borcherding,
A. G. Reiche,
K. Srivastava
and other authors.
,
S. Zafar,
J. Q. Zhou,
W. Rijnink,
H. Alshammary,
N. Borcherding,
A. G. Reiche,
K. Srivastava
and other authors.
